Biotech and Life Sciences Companies in the US

Overview

The US life sciences sector spans small biotech startups through global pharmaceutical companies, with shared requirements for specialized software, regulatory expertise, and scientific infrastructure. This audience covers 229,000+ US companies across biotech, pharmaceutical, medical devices, diagnostics, and contract research organizations — enriched with sub-sector classification, funding history, R&D focus, and verified executive and scientific leadership contacts.

What's Included

• Company Identity: Verified name, primary domain, and US headquarters
• Sub-Sector Classification: Biotech, pharmaceutical, medical devices, diagnostics, CRO, or CDMO
• Funding Profile: Stage, total raised, and most recent round date (including NIH grants for academic spinouts)
• Headcount: Employee count and 1-year growth rate
• R&D Focus: Therapeutic area or scientific domain where available (oncology, immunology, genomics, etc.)
• Leadership Contacts: Verified email and phone for C-suite, VP of R&D, VP of Clinical Operations, and CSO contacts

Use Cases

Life Sciences Platform Sales

ERP, LIMS, clinical data management, and regulatory affairs platforms have a defined buyer set within this audience. Sub-sector classification and employee count allow vendors to focus on the stage and type of company most likely to need their specific solution.

Clinical Research and CRO Services

CROs and clinical service vendors can use therapeutic area focus and pipeline stage to identify biotech and pharmaceutical companies actively running or preparing for clinical trials. Funding data helps prioritize companies with capital to deploy on outsourced research.

Healthcare Technology Sales

Electronic lab notebooks, trial management software, supply chain tools, and quality management systems all have distinct buying cycles within this sector. Use company size and sub-sector to target the right buyer with the right product positioning.

Investor Deal Sourcing

Life sciences investors can filter by sub-sector, therapeutic area, and funding stage to surface companies that fit specific portfolio mandates. Headcount growth and recency of funding provide additional signals for deal prioritization.